Hasbro reports on June 11 with the stock trading nearly 35% below the analyst consensus target — a gap that turns the print into a referendum on whether the recovery story is real or just a Street fantasy.
Options positioning reflects genuine pre-earnings defensiveness. The put/call ratio has run above 1.10 for most of the past two weeks, well above its 20-day average of 0.96. The ratio briefly touched 1.15 — its highest level of the past year — before easing fractionally. That persistent skew toward puts suggests hedging demand has been accumulating, not spiking. The stock itself closed at $84.26, down 14% over the past month, though a modest bounce over the last few days has taken some pressure off the short-term chart.
Short interest adds a second layer of concern, though the borrowing market itself is not stressed. Shorts have rebuilt aggressively — up 40% over the past month to 5.7% of free float — extending the build noted in a prior ORTEX piece from June 3. Yet borrow availability is exceptionally loose, with over 2,600% of short interest still available to lend. Cost to borrow has also dropped sharply, falling 40% in a week to under 0.30%. The lending market is sending no squeeze signal whatsoever; the short position is building in an environment where doing so costs almost nothing.
The analyst debate is asymmetric. BofA and Morgan Stanley hold Buy or Overweight ratings with targets north of $115–$123, anchored to the Sixth Wall AI-studio announcement and a forward EPS recovery the ORTEX factor model puts above 400% year-on-year improvement. Wells Fargo, notably, cut its target from $92 to $85 just yesterday — a move that now sits almost exactly at the current price. That signals the most cautious mainstream view is already priced in, while the bull camp argues the IP monetisation thesis has barely been discounted. Bears point to real regional weaknesses: North America, Asia Pacific, and Latin America all saw year-over-year sales declines, and inventory risks from tariffs haven't fully resolved. The mean target of $113.53 implies extraordinary upside from here, but that figure may carry some weight from older target entries — investors should note the divergence before reading it as a clean signal.
Insider selling adds a final note of caution. The CFO, CEO, and several other senior executives all sold in March and May at prices around $94–$95 — well above where the stock trades today. Those sales carry low significance scores and may well be pre-planned, but they do mean no one in the C-suite has been a buyer into the decline. Tomorrow's print will test whether the Sixth Wall narrative and the earnings-recovery trajectory are credible enough to close even part of that $30-plus gap between price and consensus.
See the live data behind this article on ORTEX.
Open HAS on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
